Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
- Registration Number
- NCT05040971
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes.
This study will look at how much weight participants lose, and if participants can go from having blood sugar that is higher than normal (prediabetes) to having normal blood sugar.
Semaglutide is compared to a "dummy" medicine. The "dummy" medicine looks like semaglutide but has no effect on the body.
In addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight.
Participants will either get semaglutide or "dummy" medicine - which treatment they get is decided by chance. Participants are 2 times as likely to get semaglutide as "dummy" medicine.
Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm.
The study will last for about 19 months. Participants have to take the study medicine every week for the first 12 months. The last 7 months participants will not take any medication.
Participants will have 14 clinic visits and 1 phone call with the study staff. At 9 of the clinic visits Participants will have blood samples taken. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 207
-
Male or female aged greater than or equal to 18 years at the time of signing informed consent.
-
BMI greater than or equal to 30.0 kg/m^2
-
Prediabetes defined as at least one of the following:
- HbA1c between 6.0 and 6.4 percent (42 and 47 mmol/mol) (both inclusive) as measured by central laboratory at screening.
- FPG between 5.5 and 6.9 mmol/L (99 and 125 mg/dL) (both inclusive) as measured by central laboratory at screening.
- History of type 1 or type 2 diabetes.
- Treatment with glucose-lowering agent(s) within 90 days before screening.
- HbA1c greater than or equal to 6.5 percent (greater than or equal to 48 mmol/mol) as measured by central laboratory at screening.
- FPG greater than or equal to 7.0mmol/L (126 mg/dL) as measured by central laboratory at screening.
A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records.
- Treatment with any medication for the indication of obesity within the past 90 days before screening.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Semaglutide Semaglutide 2.4 mg Participants will receive subcutaneus (s.c.) semaglutide 2.4 mg once weekly for 52 weeks Placebo (semaglutide) Placebo Participants will receive subcutaneus (s.c.) placebo (semaglutide) once weekly for 52 weeks
- Primary Outcome Measures
Name Time Method Change in Body Weight (Percentage [%]) From randomisation (week 0) to end of treatment (week 52) Change in body weight from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Participants With Change to Normoglycemia At week 52 Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 52 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: glycosylated haemoglobin (HbA1c) lesser than (\<) 6.0 percentage (%) and fasting plasma glucose (FPG) lesser than (\<) 5.5 millimoles per liter (mmol/L). 2) Pre-diabetes: 6.0% lesser than or equal (≤) HbA1c lesser than (\<) 6.5% or 5.5 mmol/L lesser than or equal (≤) FPG lesser than (\<) 7.0 mmol/L or non-verified type 2 diabetes. 3) Type 2 diabetes: HbA1c greater than or equal (≥) 6.5% or FPG greater than or equal (≥) 7.0 mmol/L.
- Secondary Outcome Measures
Name Time Method Change in Glycosylated Haemoglobin (HbA1c) From randomisation (week 0) to end of treatment (week 52) Change in glycosylated haemoglobin (HbA1c) from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Change in Fasting Plasma Glucose (FPG) From randomisation (week 0) to end of treatment (week 52) Change in fasting plasma glucose (FPG) from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Change in Waist Circumference From randomisation (week 0) to end of treatment (week 52) Change in waist circumference from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Change in Systolic Blood Pressure From randomisation (week 0) to end of treatment (week 52) Change in systolic blood pressure from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Change in Triglycerides (Millimoles Per Liter [mmol/L]) - Ratio to Baseline From randomisation (week 0) to end of treatment (week 52) Change in triglycerides (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Change in Total Cholesterol (mmol/L) - Ratio to Baseline From randomisation (week 0) to end of treatment (week 52) Change in total cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Change in High Density Lipoprotein (HDL) Cholesterol (mmol/L) - Ratio to Baseline From randomisation (week 0) to end of treatment (week 52) Change in high density lipoprotein (HDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Change in Low Density Lipoprotein (LDL) Cholesterol (mmol/L) - Ratio to Baseline From randomisation (week 0) to end of treatment (week 52) Change in low density lipoprotein (LDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Change in Very Low Density Lipoprotein (VLDL) Cholesterol (mmol/L) - Ratio to Baseline From randomisation (week 0) to end of treatment (week 52) Change in very low density lipoprotein (VLDL) cholesterol (measured in mmol/L) from randomisation (week 0) to end of treatment (week 52) is presented as ratio to baseline. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Change in Body Weight (Kilogram [Kg]) From randomisation (week 0) to week 52 Change in body weight from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 5% (Yes/No) At week 52 Participants who achieved body weight reduction greater than or equal to 5% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 10% (Yes/No) At week 52 Participants who achieved body weight reduction greater than or equal to 10% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 15% (Yes/No) At week 52 Participants who achieved body weight reduction greater than or equal to 15% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Participants Achieving Body Weight Reduction Greater Than or Equal (≥) 20% (Yes/No) At week 52 Participants who achieved body weight reduction greater than or equal to 20% (Yes/No) at week 52 is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Change in Pulse From randomisation (week 0) to end of treatment (week 52) Change in pulse from randomisation (week 0) to end of treatment (week 52) is presented. The endpoint was evaluated based on the data from in-trial observation period which was defined as the time period where the participant was assessed in the main phase of the study. The 'in-trial' (main phase) observation period for a participant begins on the date of randomisation and ends at the first of the following dates (both inclusive): safety visit, withdrawal of consent, last contact with participant (for participants lost to follow-up), death.
Trial Locations
- Locations (30)
University of Calgary
🇨🇦Calgary, Alberta, Canada
C-endo Diab Endo Clin Calgery
🇨🇦Calgary, Alberta, Canada
LMC Clin Res Inc. Thornhill
🇨🇦Concord, Ontario, Canada
Wharton Med Clin Trials
🇨🇦Hamilton, Ontario, Canada
Ocean West Research Clinic
🇨🇦Surrey, British Columbia, Canada
G.A. Research Associates Ltd.
🇨🇦Moncton, New Brunswick, Canada
LMC ClinRsrh Inc.Brampton
🇨🇦Brampton, Ontario, Canada
Hamilton Med Res Group
🇨🇦Hamilton, Ontario, Canada
Milestone Research
🇨🇦London, Ontario, Canada
Toronto Sleep Institute/MedSleep
🇨🇦Toronto, Ontario, Canada
Diabetes Heart Research Centre
🇨🇦Toronto, Ontario, Canada
Centre Medical Acadie
🇨🇦Montreal, Quebec, Canada
LMC Clin Rsrch Inc. (Montreal)
🇨🇦Saint-Laurent, Quebec, Canada
Centre de recherché du CHUS
🇨🇦Sherbrooke, Quebec, Canada
Ctr de Med Metab de Lanaudiere
🇨🇦Terrebonne, Quebec, Canada
Aarhus Universitetshospital Diabetes og Hormonsygdomme
🇩🇰Aarhus N, Denmark
Hvidovre Hospital Endokrinologisk forsknings afsnit 159
🇩🇰Hvidovre, Denmark
Obesity Research Unit
🇫🇮Helsinki, Finland
StudyCor
🇫🇮Jyväskylä, Finland
Hospital Gregorio Marañón
🇪🇸Madrid, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Hospital Infanta Luisa
🇪🇸Sevilla, Spain
Clifton Medical Centre
🇬🇧Rotherham, South Yorkshire, United Kingdom
The Health Centre
🇬🇧Bradford-on-Avon, United Kingdom
WISDEM Centre
🇬🇧Coventry, United Kingdom
Claremont Medical Practice
🇬🇧Exmouth, United Kingdom
GP Direct
🇬🇧Harrow, United Kingdom
Guys Hospital
🇬🇧London, United Kingdom
The Staploe Medical Centre
🇬🇧Soham, United Kingdom
MyHealth
🇬🇧Strensall, United Kingdom